Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study.

Celia A J MichielsensNathan den BroederMichelle L M MulderFrank H J van den HoogenLise M VerhoefAlfons A den Broeder

Published in: Rheumatology (Oxford, England) (2021)

T2T tapering of TNFi reduces drug exposure and has no negative effects on disease activity in PsA and axSpA patients compared with full dose continuation.

Keyphrases

disease activity
systemic lupus erythematosus
rheumatoid arthritis
ankylosing spondylitis
end stage renal disease
rheumatoid arthritis patients
ejection fraction
chronic kidney disease
newly diagnosed
juvenile idiopathic arthritis
prognostic factors
peritoneal dialysis
drug induced